biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > 2-million-dollar fee

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 20, 2023 2:14pm

98 Views

Post# 35236122

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2-million-dollar fee

Thanks, OttawaPeter. If capturing xB3 isn't Lind's objective, then it won't really hurt them or cost them to give Bioasis some time.

Also, it may be unlikely, but the Lind debt, in whole or in part, could be exchanged for equity. Again, I think new management may be required before Lind might consider that.

I didn't write that piece to project optimism. I think there are low odds of Bioasis surviving this.

jd

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing